Innate immune cells at the injection site

Innate immune cells at the injection site refer to the localized population of leukocytes, including neutrophils, monocytes, macrophages, and dendritic cells, that respond to the administration of vaccines or injectable therapeutic agents. Upon injection, these cells are rapidly recruited from the circulation and surrounding tissues in response to physical tissue damage or the presence of immunostimulatory molecules such as adjuvants (Awate et al., 2013, doi:10.3389/fimmu.2013.00114). These cells function by sensing danger-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors (PRRs), leading to the secretion of pro-inflammatory cytokines and chemokines that orchestrate the subsequent adaptive immune response (Liang et al., 2020, doi:10.1038/s41577-020-0338-y). While this localized innate response is essential for the efficacy of many vaccines by facilitating antigen presentation, it is also the primary driver of common adverse events known as injection site reactions, such as swelling and pain (Kohl et al., 2003, doi:10.1016/S0264-410X(02)00702-8). This entity is not a single molecular target but rather a physiological compartment and cellular process critical for immunopharmacology. Understanding the kinetics and composition of these cells is vital for optimizing drug delivery systems and vaccine formulations to maximize immunogenicity while minimizing local toxicity.

Other names

Injection site immune cellsLocal innate immune responseInfiltrating leukocytes at injection siteInjection site microenvironment

Recruitment and activation of innate immune cells (neutrophils, monocytes, dendritic cells) to the site of administration to enhance antigen uptake, processing, and the subsequent induction of adaptive immunity.